John T Slevin
Affiliation: University of Kentucky
- Trichloroethylene: Parkinsonism and complex 1 mitochondrial neurotoxicityDon M Gash
Department of Anatomy and Neurobiology, University of Kentucky, Lexington, KY 40536, USA
Ann Neurol 63:184-92. 2008..To analyze a cluster of 30 industrial coworkers with Parkinson's disease and parkinsonism subjected to long-term (8-33 years) chronic exposure to trichloroethylene...
- The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD studyJeanne C Latourelle
Department of Neurology, Boston University School of Medicine, Boston University, Boston, MA, USA
BMC Med 6:32. 2008..Studies of the penetrance of LRRK2 mutations have produced a wide range of estimates, possibly due to differences in study design and recruitment, including in particular differences between samples of familial PD versus sporadic PD...
- Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factorJohn T Slevin
Department of Anatomy and Neurobiology, Morris K Udall Parkinson s Disease Research Center of Excellence, University of Kentucky, Lexington 40536 0284, USA
J Neurosurg 102:216-22. 2005..In the present study the authors report on a 6-month unilateral intraputaminal GDNF infusion in 10 patients with advanced Parkinson disease (PD)...
- Unilateral intraputaminal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year each of treatment and withdrawalJohn T Slevin
Department of Anatomy and Neurobiology, The Morris K Udall Parkinson s Disease Research Center of Excellence, and the Magnetic Resonance Imaging and Spectroscopy Center, University of Kentucky, Lexington, Kentucky 40536 0284, USA
Neurosurg Focus 20:E1. 2006..After the trial was halted by the sponsor, the patients were monitored for an additional year to evaluate the effects of drug withdrawal...
- Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawalJohn T Slevin
Department of Neurology, University of Kentucky, Chandler Medical Center, Lexington, Kentucky 40536 0284, USA
J Neurosurg 106:614-20. 2007..After the trial was halted by the drug sponsor, the patients were monitored for an additional 1 year during which the effects of drug withdrawal were evaluated...
- Validation studies of the human movement analysis panel for hand/arm performanceCharles D Smith
Department of Biomedical Engineering, University of Kentucky, Lexington, KY 40536, USA
J Neurosci Methods 165:287-96. 2007..The HMAP has a smaller version used in primates, so that measurements made in primate models of disease and its treatment are directly comparable to analogous clinical measurements made in the corresponding human disease...
- Restless legs syndromeMelody Ryan
Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, KY 40536, USA
Am J Health Syst Pharm 63:1599-612. 2006..The signs and symptoms, epidemiology, etiology, pathophysiology, diagnosis, pharmacologic and nonpharmacologic treatments, and options and guidelines for the treatment of restless legs syndrome (RLS) are reviewed...
- Trichloroethylene and Parkinson diseaseFariha Zaheer
Movement Disorders Program, Department of Neurology, University of Kentucky College of Medicine, Kentucky Clinic L 445, 740 South Limestone Street, Lexington, KY 40536 0284, USA
Neurol Clin 29:657-65. 2011..These observations endorse the hypothesis that a variety of environmental risk factors may cause nigrostriatal degeneration and clinical parkinsonism in genetically predisposed individuals...
- Emotional dysfunction in Parkinson's diseaseLee X Blonder
Sanders Brown Center on Aging and Departments of Behavioral Science and Neurology, University of Kentucky College of Medicine, Lexington, USA
Behav Neurol 24:201-17. 2011..In this review we discuss the neuropsychiatric abnormalities that accompany Parkinson's disease and describe their neuropsychological, neuropharmacologic, and neuroimaging concomitants...
- Kindling-induced asymmetric accumulation of hippocampal 7S SNARE complexes correlates with enhanced glutamate releaseElena A Matveeva
Departments of Molecular and Cellular Biochemistry, University of Kentucky Medical Center, Lexington, Kentucky, USA
Epilepsia 53:157-67. 2012..To correlate kindling-associated alterations of the neurotransmitter secretory machinery, glutamate release in the trisynaptic hippocampal excitatory pathway, and the behavioral evolution of kindling-induced epileptogenesis...
- Levetiracetam prevents kindling-induced asymmetric accumulation of hippocampal 7S SNARE complexesElena A Matveeva
Department of Molecular and Cellular Biochemistry, University of Kentucky, Medical Center, Lexington, Kentucky, USA
Epilepsia 49:1749-58. 2008..The present studies probe the persistence of 7SC accumulation and the effect of the anticonvulsant, levetiracetam (LEV), on 7SC and SNARE regulators...
- Research on Parkinson diseaseJohn T Slevin
J Neurosurg 102:401. 2005
- A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's diseasePaul A Nausieda
Wisconsin Institute for Neurologic and Sleep Disorders, Regional Parkinson Center, Milwaukee, Wisconsin, USA
Clin Ther 27:58-63. 2005..In these patients, orally disintegrating tablets (ODTs) can be given without water and may provide greater convenience and ease of use than conventional tablets...
- Reply: GDNF poses troubling questions for doctors, drug makerJohn T Slevin
Ann Neurol 59:989-90. 2006
- Replication of association between ELAVL4 and Parkinson disease: the GenePD studyAnita L Destefano
Department of Biostatistics, Boston University School of Public Health, 715 Albany Street, Crosstown Center, 3rd Floor, Boston, MA 02118, USA
Hum Genet 124:95-9. 2008..This replication of association with rs967582 in a third cohort further implicates ELAVL4 as a PD susceptibility gene...